FINDEX Inc. announced that at an extraordinary meeting of the Board of Directors held on May 6, 2022, the Company resolved to enter into a strategic partnership agreement with Toyota Tsusho Corporation ((hereafter referred to as Toyota Tsusho) regarding medical information system business and health tech business and entered into the agreement on the same date. Reason for alliance: Towards better society, at such a momentous time, They are committed to improve the convenience and efficiency of medical exam at healthcare organizations overseas, as well as early detection of optical diseases, and educational activities in Japan, in collaboration with Toyota Tsusho, who has built up relationships of trust through their wide variety of businesses around the world. solutions.

(i) Overseas sales of medical information solutions: As the geographical strategies, the company will sell medical information platform, mainly flagship product "Claio" (image filing system), to key healthcare organizations in India and the ASEAN region. It will establish a cordial support system in collaboration with local medical system companies to ensure efficient and sustainable delivery of product and service. In June 2022, It will introduce Claio, on a trial basis, to Sakra World Hospital in India, which Toyota Tsusho has its investment stake, and begin test operations.

With a population of over 1.3 billion, the healthcare market of India has an unprecedented scalability, and at the same time, there remain a lot of issues that can be ameliorated by digitalization. Addressing challenges to solve issues out there, it will contribute to the realization of a sustainable society by improving the quality of medical care and the efficiency of hospital management. (ii) Introduction of "GAP-screener" (gaze analyzing perimeter/regulatory product) to health checkup facilities in Japan: GAP-screener", which was commercialized for optional use during health checkups, will be introduced to domestic health checkup facilities and multiphasic health screening facilities under Toyota Tsusho's sales strategy.

This product is original invention, darkroom-free, objective optical testing device. By permanently exhibiting this solution other than ophthalmology facilities, more convenient testing will be enabled, leading to the early detection of glaucoma. It will also utilize the visual field data obtained through the test, for various possibilities in future research and development in the medical field, such as the establishment of new treatment methods.